Novartis’ Exjade gets committee review
Executive Summary
Novartis' oral iron chelator Exjade (deferasirox) will be reviewed for treatment of chronic iron overload during blood transfusions by FDA's Blood Products Advisory Committee on Sept. 29. Panel will likely discuss Exjade's failure to demonstrate non-inferiority to Novartis' current iron overload therapy Desferal in the pivotal study. The meeting will be held at the CDER advisory committee conference room at 5630 Fishers Lane in Rockville, Md. beginning at 8 a.m.[Editor's note: To 1watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com or call 800-627-8171.]...